{"id":"metronidazole-based-quadriple-therapy","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Metallic taste"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Headache"},{"rate":"null","effect":"Dark stool (from bismuth)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole acts as a nitroimidazole antimicrobial that disrupts bacterial DNA in H. pylori. The quadruple regimen enhances efficacy by combining metronidazole's bactericidal activity with a proton pump inhibitor to reduce gastric acid (creating optimal conditions for drug activity), a bismuth compound for additional antimicrobial and mucosal protective effects, and a second antibiotic to overcome resistance and improve eradication rates. This multi-drug approach targets H. pylori through synergistic mechanisms.","oneSentence":"Metronidazole-based quadruple therapy combines metronidazole with three other agents (typically a proton pump inhibitor, bismuth compound, and tetracycline or clarithromycin) to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppressive mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:05.562Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication in peptic ulcer disease"},{"name":"H. pylori-associated chronic gastritis"}]},"trialDetails":[{"nctId":"NCT04769583","phase":"PHASE4","title":"14-day Quadruple Therapy Versus Triple Therapy in HP Eradication","status":"COMPLETED","sponsor":"mohamed bouchoucha","startDate":"2019-02-10","conditions":"Gastritis H Pylori","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["concomitant quadruple therapy (QC)"],"phase":"marketed","status":"active","brandName":"metronidazole based quadriple therapy","genericName":"metronidazole based quadriple therapy","companyName":"mohamed bouchoucha","companyId":"mohamed-bouchoucha","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metronidazole-based quadruple therapy combines metronidazole with three other agents (typically a proton pump inhibitor, bismuth compound, and tetracycline or clarithromycin) to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppressive mechanisms. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}